Wordt geladen...

PCI-32765, the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials

Ibrutinib is a potent covalent kinase inhibitor that targets BTK. BTK, or Bruton’s tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia. Ibrutinib has modest cytotoxicity again...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteur: Brown, Jennifer R
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3584329/
https://ncbi.nlm.nih.gov/pubmed/23296407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11899-012-0147-9
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!